

Development And Bioproduction Of Protein Containing The Caseinphospho-peptide For Anti-osteoporosis

顏品澄、簡宏堅

E-mail: 364884@mail.dyu.edu.tw

ABSTRACT

Anti-osteoporosis phosphopeptide (CPP) is discovered from the casein protein of milk. Only α -casein has anti-osteoporosis activity in casein protein including α 1-casein, α 2-casein, β -casein, and κ -casein. β -casein was digested into 25 amino acid peptide by protease in the small intestine. A partial casein protein was precipitated with the calcium phosphate salts because the member is growing too big, caused the small intestine to be unable to absorb the casein protein with the calcium phosphate union macro-molecule. Casein protein was phosphorylated by casein kinase (CK) in mammary gland and then enters the small intestine to be digested into casein phosphopeptide. Only casein phosphopeptide was bound with calcium ions, and then absorbed by the small intestine. Therefore this laboratory use CKI to phosphorylate casein protein, and help casein phosphopeptide to bind with calcium ions and to be absorbed in the small intestine. Casein phosphopeptide R E L E E L N V P G E I V E S L S S S E E S I T R with four serine amino acid phosphorylated as indicated can bind with calcium ions to promote the absorption. In order to establish the high yield and the highly concentrated quantity producer type of CPP peptide, this laboratory uses the human tyrosine hydroxylase (HTH) to carry the casein phospho peptide, and also seeks HTH not to affect its activity when its five domains was replaced for the casein phosphopeptide. As well as the N and C terminals of casein phosphopeptide are designed Phe to favor the future to be cut with pepsin for releasing the free casein phosphopeptide absorbed directly in the duodenum. Therefore we first carry on the design of primers for replacement and construction of casein phosphopeptide, and use overlap-PCR technique to construct the replacement of five domains for casein phosphopeptide, respectively, and then, insert in the pQE30 and unite five domains of casein phosphopeptide in one CPP-HTH. Gene expression system of pYLSC1-5S was used to reclone CPP-HTH and insert in the 5S-rDNA of *Yarrowia lipolytica* chromosome, called Y-CPP yeast. One the other hand we choose the CK1 gene to clone into internal secretion system of pYLEX1 and insert in the leucine biosynthetic gene of Y-CPP yeast, called Y-CPP-CK yeast, for bioproduction of casein phosphopeptide. The growth curve of Y-CPP and Y-CPP-CKI in growth medium were determined to be 16 h for the optimal growth with the spectrophotometer. The induction curve of Y-CPP and Y-CPP-CK growing in the inducing medium were determined to be 36 h for the massive production of CPP-HTH with the analysis of HPLC. The peptidyl protein CPP-HTH was concentrated by using the corn starch adsorption. The molecular weight of CPP-HTH is theoretically 54.6 kDa, however, the translation modification in the *Y.lipolytica* is to make its molecular weight to increase approximately 10 kDa. Therefore, the molecular weight of CPP-HTH is analyzed approximately 64.6 kDa with SDS-PAGE, but if CPP-HTH is phosphorylated by CKI to gain slightly high 64.6 kDa, if joins calcium ions consecutively to make even higher molecular weight.

Keywords : *Yarrowia lipolytica*

Table of Contents

目錄 封面內頁 簽名頁 中文摘要.....	iii	英文摘要.....	v	誌謝.....	vii	目錄.....	viii	圖目	
錄.....	xiv	表目錄.....	xix	1. 前言.....	1	1.1 胜?.....	1	1.1.1 生物活性?的來源及應用.....	1
1.1.2 生物活性胜?(bioactive peptide)的生產.....	2	1.2 Y. lipolytica胞外分泌系統.....	2	1.3 人類酪胺酸?基酵素.....	4	2. 研究動		機.....	5
3. 材料與方法.....	7	3.1 材料.....	7	3.1.1 菌種及質體.....	7	3.1.2 藥品.....	7	3.1.3	
酵素.....	7	3.2 實驗設計流程.....	8	3.2.1 引子設計(primer design).....	8	3.2.1.1 共同引子設計之注意事		項.....	8
3.2.1.2 自設引子設計之注意事項.....	9	3.2.2 實驗流程設計.....	9	3.3 實驗方法.....	10	3.3.1 小量質體DNA製備.....	10	3.3.2 快速質體DNA抽取套組.....	11
3.3.3 瓊脂凝膠電泳(agarose gel		lectrophoresis).....	12	3.3.4 聚合?鏈鎖反應(Polymerase chain reaction PCR).....	12	3.3.5 重疊式聚合?鏈鎖反應(overlap polymerase		chain reaction).....	14
3.3.6 DNA片段的回收及純化.....	15	3.3.7 限制酵素剪切.....	16	3.3.8 DNA黏接作用.....	16	3.3.9 E.coli勝		任細胞的製備.....	16
3.3.10 轉入到大腸桿菌的 NovaBlue.....	17	3.3.11 採用聚合?鏈反應篩選出正確的基因.....	17	3.3.12		DNA 基因定序.....	18	3.3.13 多組基因插入酵母菌染色體.....	19
3.3.14 構築能插入5S-RNA基因又胞外分泌		的pYLSC1-5s表現載體.....	19	3.3.15 將82組Gentomycin基因置換成胜?蛋白基因.....	20	3.3.16 將CKI選殖入胞內分泌		的pYLEX1表現載.....	21
3.3.17 將CKI插入82組CPP-HTH基因的酵母菌 Y. lipolytica.....	21	3.3.18 轉入到酵母菌中的方		法.....	21	3.3.19 基因表現.....	22	3.3.20 蛋白透析.....	22
3.3.21 玉米澱粉沉澱回收.....	23								

3.3.22 聚丙烯醯胺凝膠電泳分析.....	23	4. 結果.....	25	4.1 尋找CPP勝?置換區段.....	25
4.1.1 五大區段之序列置換位分析.....	25	4.2 基因選殖.....	26	4.2.1 單套抗骨質疏鬆勝?序列置換到第一區段HTH (CPP 1).....	26
4.2.2 單套抗骨質疏鬆勝?序列置換到第二區段HTH (CPP 2).....	27	4.2.3 單套抗骨質疏鬆勝?序列置換到第三、四區段HTH (CPP 34).....	27	4.2.4 單套抗骨質疏鬆勝?序列置換到第五區段HTH (CPP 5).....	28
4.2.5 連結抗骨質疏鬆勝?序列第一、二區段(CPP1-2).....	28	4.2.6 連結抗骨質疏鬆勝?序列第三、四、五區段(CPP 34-5).....	29	4.2.7 連結抗骨質疏鬆勝?第一、二區段及三、四、五區段(CPP 12-345).....	29
4.2.8 選殖抗骨質疏鬆勝?CPP1-5於pYLSC1-5s表現載體(CPP-SC).....	30	4.2.9 轉型抗骨質疏鬆勝?CPP-SC於Y. lipolytica此酵母菌命名為(Y-CPP).....	30	4.2.10 將一組CKI插入82組CPP-HTH基因的酵母菌Y-CPP得到此酵母菌為Y-CPP-CKI.....	30
4.3 基因表現.....	31	4.3.1 Y. lipolytica之生長曲線.....	31	4.3.2 SDS-PAGE之蛋白質分子量預測.....	31
5. 結論.....	33	5.1 酪蛋白磷酸化勝?之蛋白質開發.....	33	5.2 未來工作.....	33
參考文獻.....	100	圖目錄	100	圖1. 實驗流程設計.....	35
圖2. 5s轉殖PQE30示意圖.....	36	圖3. 5s經基因選殖後委託生技公司定序之比對.....	37	圖4. Gentomycin 抗藥基因轉殖入5s-PQE30之示意圖.....	38
圖5. Gentomycin 抗藥基因轉殖入5s-PQE30委託生技公司定序之比對.....	39	圖6. Gentomycin resistant-5s轉殖酵母菌示意圖.....	40	圖7. GF1-5S以1.10.100.1000.10000倍抗生素培養置換到酵母菌中.....	41
圖8. Gentomycin resistant-5s酵母菌PCR比對82組基.....	42	圖9. CPP-HTH-6H-pYLSC1-5S基因轉殖入GF1-5S置換Gentomycin 抗藥基因的抗藥性比對.....	43	圖10. 5s-L和5s-R轉殖pYLSC1之示意圖.....	44
圖11. 5s-L 轉殖pYLSC1委託生技公司定序之比對.....	45	圖12. 5s-R轉殖pYLSC1委託生技公司定序之比對.....	46	圖13. CPP-HTH-6H轉殖pYLSC1-5S委託生技公司定序之比對.....	47
圖14. CPP-HTH-6H轉殖pYLSC1-5S胺基酸比對.....	48	圖15. CKI轉殖pYLEX1示意圖.....	49	圖16. CKI轉殖pYLEX1委託生技公司定序之比對.....	50
圖17. CKI轉殖酵母菌示意圖.....	51	圖18. CPP勝?可置換之五大區段示意圖.....	52	圖19. 更換表現載體之示意圖.....	53
圖20. E. coli系統之pQE30表現載體.....	54	圖21. 第一區段 頭段與尾段DNA回收於瓊脂凝膠電泳.....	55	圖22. 第一區段經overlapping PCR於瓊脂凝膠電泳.....	56
圖23. 第一區段經篩查聚合?鏈反應於瓊脂凝膠電泳.....	57	圖24. 第一區段經基因選殖後委託生技公司定序之比對.....	58	圖25. 第二區段頭段與尾段DNA回收於瓊脂凝膠電泳.....	59
圖26. 第二區段經overlapping PCR於瓊脂凝膠電泳.....	60	圖27. 第二區段經篩查聚合?鏈反應於瓊脂凝膠電泳.....	61	圖28. 第二區段陽性菌抽出質體後進行限制?切割於瓊脂凝膠電泳.....	62
圖29. 第二區段經基因選殖後委託生技公司定序之比對.....	63	圖30. 第三、四區段頭段與尾段DNA回收於瓊脂凝膠電泳.....	64	圖31. 第三、四區段經overlapping PCR於瓊脂凝膠電泳.....	65
圖32. 第三、四區段經篩查聚合?鏈反應於瓊脂凝膠電泳.....	66	圖33. 第三、四區段陽性菌抽出質體後進行限制?切割於瓊脂凝膠電泳.....	67	圖34. 第三、四區段經基因選殖後委託生技公司定序之比對.....	68
圖35. 第五區段頭段與尾段DNA回收於瓊脂凝膠電泳.....	69	圖36. 第五區段經overlapping PCR於瓊脂凝膠電泳.....	70	圖37. 第五區段經篩查聚合?鏈反應於瓊脂凝膠電泳.....	71
圖38. 第五區段經基因選殖後委託生技公司定序之比對.....	72	圖39. 第一和第二區段連接之頭段及尾段DNA片段回收於瓊脂凝膠電泳.....	73	圖40. 第一和第二區段連接經overlapping PCR於瓊脂凝膠電泳.....	74
圖41. 第一和第二區段連接經篩查聚合?鏈反應於瓊脂凝膠電泳.....	75	圖42. 第一和第二區段連接經基因選殖後委託生技公司定序之比對.....	76	圖43. 第三四和第五區段連接之頭段及尾段DNA片段回收於瓊脂凝膠電泳.....	77
圖44. 第三四和第五區段連接經overlapping PCR於瓊脂凝膠電泳.....	78	圖45. 第三四和第五區段連接經篩查聚合?鏈反應於瓊脂凝膠電泳.....	79	圖46. 第三四和第五區段連接經基因選殖後委託生技公司定序之比對.....	80
圖47. 第一二和第三四五區段連接之頭段及尾段DNA片段回收於瓊脂凝膠電泳.....	81	圖48. 第一二和第三四五區段連接經overlapping PCR於瓊脂凝膠電泳.....	82	圖49. 第一二和第三四五區段連接經篩查聚合?鏈反應於瓊脂凝膠電泳.....	83
圖50. 第一二和第三四五區段經基因選殖後委託生技公司定序之比對.....	84	圖51. pO1g、Y-CPP、Y-CPP-CKI生長曲線.....	85	圖52. SDS之CPP、CKI+CPP、CKI+CPP+CaCl ₂ 之子量比較.....	86
表目錄	87	表1. 本研究所用之primers.....	87	表2. 菌種與菌體.....	89
表3. 本實驗所使用之藥劑方.....	91	附錄	91	附錄1. Yarrowia lipolytica胺基酸編碼使用頻率.....	98

REFERENCES

- Choi, H.-I., Kim, H.-J., Park, J.-I., Shin, E.-H., Kim, D.-W. and Kim, S.-S. Design and efficient synthesis of novel ascorbyl conjugated peptide with high collagen biosynthesis stimulating effects. *Bioorg. Med. Chem. Lett.* 2009, 19(7):2079 – 2082.
- Claudia Gravaghi¹, Elena Del Favero¹, Laura Cantu¹, Elena Donetti², Marzia Bedoni², Amelia Fiorilli¹, Guido Tettamanti¹, Anita Ferraretto¹. Casein phosphopeptide promotion of calcium uptake in HT-29 cells - relationship between biological activity and supramolecular structure, Article first published online: 29 AUG 2007 DOI: 10.1111/j.1742-4658.2007.06015.x
- Madzak C, Gaillardin C, Beckerich JM. Heterologous protein expression and secretion in the non-conventional yeast *Yarrowia lipolytica*: a review. *J Biotechnol*, 2004, 109(1-2):63-81
- Meisel, H.1,* and FitzGerald, R. J2. Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects, *Current Pharmaceutical Design*, 2003, 9, 1289-1295
- Sambrook J, and Russell D.W. *Molecular cloning : a laboratory manual*, third edition. Cold spring harbor laboratory press, 2001. New York.
- Goodwill KE, Sabatier C, Stevens RC. Crystal Structure of Tyrosine Hydroxylase with Bound Cofactor Analogue and Ironat 2.3 Å Resolution: Self-Hydroxylation of Phe300 and the Terin-Binding Site. *Biochemistry*, 1998, 37(39):13437-13445.
- Kenneth E. Goodwill, Christelle Sabatier, and Raymond C. Stevens. Crystal Structure of Tyrosine Hydroxylase with Bound Cofactor Analogue and Ironat 2.3 Å Resolution: Self-Hydroxylation of Phe300 and the Pterin-Binding Site. *Biochemistry*. 1998, 37(39):13437-13445.
- Manley CH, and Ahmedi S. The development of process flavors. *Trends Food Sci Technol*. 1995, 6(2):46-51.
- Katayama, K., Armendariz-Borunda, J., Raghov, R., Kang, A.H.

and Seyer, J.M. A pentapeptide from type I procollagen promotes extracellular matrix production. *J. Biol. Chem.* 1993 ,268(14):9941 – 9944 . 10.
Katayama, K., Seyer, J.M., Raghow, R. and Kang, A.H. Regulation of extracellular matrix production by chemically synthesized subfragments of type I collagen carboxy propeptide. *Biochemistry.* 1991 ,30(29):7097 – 7104 . 11. Nishimura A., Morita M., Nishimura Y.,and Sugino Y. A rapid and hifhly efficient method for preparation of competent *Escherichia coli* cells.*Nucleic acid research.* 1990 , 18:61-69.